Predicting Long-Term Outcome of Patients of Early Parkinsonism with Acute Levodopa Challenge Test. 2021

Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
Department of Neurology, Bangur Institute of Neuroscience and Institute of Post Graduate Medical Education and Research (IPGME&R), Kolkata, West Bengal, India.

OBJECTIVE The aim of this study was to evaluate the sensitivity and specificity of various outcomes of acute levodopa challenge test (ALCT) namely improvement of motor function, development of dyskinesia and intolerance; to predict the diagnosis of idiopathic Parkinson's disease (IPD) or Parkinson-plus syndrome; to predict levodopa responsiveness and levodopa-induced dyskinesia (LID) during long-term therapy. METHODS ALCT was performed on 89 patients with parkinsonism of <2 years and were followed up for 18 months. Improvement of UPDRSm by ≥30% was considered positive. RESULTS The test was positive in 37 (43.5%) and negative in 48 (56.5%) of 85 patients completing it. Of the 75 patients completing 18 months' follow-up 34 (45.3%) were diagnosed as IPD. A positive ALCT predicted a clinical diagnosis of IPD with sensitivity and specificity of 97.4% and 70.7% respectively. The predictive value of ALCT for long-term levodopa responsiveness was less than predicting a diagnosis of IPD. While appearance of dyskinesia during ALCT had a low predictive value for future LID (sensitivity 14.3%), it had high predictive value for a diagnosis of multisystem atrophy (MSA) (91% specificity and 37.5% sensitivity). The appearance of symptoms of levodopa intolerance (SLI) during ALCT could predict a clinical diagnosis of MSA with high specificity (95.5%) and moderate sensitivity (50%). CONCLUSIONS Levodopa responsiveness during ALCT was useful in predicting a diagnosis of IPD but not long-term response to levodopa. The development of dyskinesia during ALCT could not correctly predict LID, but could predict a diagnosis of MSA. The appearance of SLI during ALCT could also predict MSA correctly.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D019578 Multiple System Atrophy A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92) Multiple System Atrophy Syndrome,Multisystem Atrophy,Multisystemic Atrophy,Atrophies, Multisystem,Atrophies, Multisystemic,Atrophy, Multiple System,Atrophy, Multisystem,Atrophy, Multisystemic,Multiple System Atrophies,Multisystem Atrophies,Multisystemic Atrophies
D020734 Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA. Autosomal Recessive Juvenile Parkinsonism,Familial Juvenile Parkinsonism,Parkinsonian Syndrome,Parkinsonism,Parkinsonism, Experimental,Parkinsonism, Juvenile,Ramsay Hunt Paralysis Syndrome,Autosomal Dominant Juvenile Parkinson Disease,Autosomal Dominant Juvenile Parkinsonism,Autosomal Dominant Parkinsonism,Autosomal Recessive Juvenile Parkinson Disease,Autosomal Recessive Parkinsonism,Chromosome 6-Linked Autosomal Recessive Parkinsonism,Experimental Parkinson Disease,Experimental Parkinsonism,Experimental Parkinsonism, MPTP-Induced,Familial Parkinson Disease, Autosomal Recessive,Juvenile Parkinson Disease,Juvenile Parkinson Disease, Autosomal Dominant,Juvenile Parkinson Disease, Autosomal Recessive,Juvenile Parkinsonism, Autosomal Dominant,Juvenile Parkinsonism, Autosomal Recessive,MPTP-Induced Experimental Parkinsonism,Parkinson Disease 2,Parkinson Disease 2, Autosomal Recessive Juvenile,Parkinson Disease Autosomal Recessive, Early Onset,Parkinson Disease, Autosomal Dominant. Juvenile,Parkinson Disease, Experimental,Parkinson Disease, Familial, Autosomal Recessive,Parkinson Disease, Juvenile,Parkinson Disease, Juvenile, Autosomal Dominant,Parkinson Disease, Juvenile, Autosomal Recessive,Parkinsonian Diseases,Parkinsonian Syndromes,Parkinsonism, Early Onset, with Diurnal Fluctuation,Parkinsonism, Early-Onset, With Diurnal Fluctuation,Parkinsonism, Juvenile, Autosomal Dominant,Parkinsonism, Juvenile, Autosomal Recessive,Chromosome 6 Linked Autosomal Recessive Parkinsonism,Diseases, Experimental Parkinson,Dominant Parkinsonism, Autosomal,Experimental Parkinson Diseases,Experimental Parkinsonism, MPTP Induced,Experimental Parkinsonisms,Juvenile Parkinsonism,Juvenile Parkinsonism, Familial,Juvenile Parkinsonisms,MPTP Induced Experimental Parkinsonism,Parkinson Diseases, Experimental,Parkinsonism, Autosomal Dominant,Parkinsonism, Autosomal Recessive,Parkinsonism, Familial Juvenile,Parkinsonism, MPTP-Induced Experimental,Parkinsonisms, Experimental,Parkinsonisms, Juvenile,Recessive Parkinsonism, Autosomal
D020820 Dyskinesias Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES. Asterixis,Ballismus,Hemiballismus,Involuntary Movements,Lingual-Facial-Buccal Dyskinesia,Orofacial Dyskinesia,Abnormal Movements,Hemiballism,Linguofacial Dyskinesia,Oral Dyskinesia,Oral-Facial Dyskinesia,Tardive Oral Dyskinesia,Abnormal Movement,Dyskinesia,Dyskinesia, Lingual-Facial-Buccal,Dyskinesia, Linguofacial,Dyskinesia, Oral,Dyskinesia, Oral-Facial,Dyskinesia, Orofacial,Dyskinesias, Lingual-Facial-Buccal,Dyskinesias, Linguofacial,Dyskinesias, Oral,Dyskinesias, Oral-Facial,Dyskinesias, Orofacial,Involuntary Movement,Lingual Facial Buccal Dyskinesia,Lingual-Facial-Buccal Dyskinesias,Linguofacial Dyskinesias,Movement, Abnormal,Movement, Involuntary,Movements, Abnormal,Movements, Involuntary,Oral Dyskinesias,Oral Facial Dyskinesia,Oral-Facial Dyskinesias,Orofacial Dyskinesias,Tardive Oral Dyskinesias

Related Publications

Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
June 2009, Parkinsonism & related disorders,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
December 1971, Postgraduate medicine,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
October 1980, Neurology,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
January 2000, European neurology,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
January 2024, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
January 2021, Frontiers in aging neuroscience,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
August 1975, Vrachebnoe delo,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
October 1970, Wisconsin medical journal,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
November 1976, Journal of neurology, neurosurgery, and psychiatry,
Mrinal Acharya, and Subhadeep Banerjee, and Apratim Chatterjee, and Adreesh Mukherjee, and Samar Biswas, and Goutam Gangopadhyay, and Atanu Biswas
July 1988, Annals of neurology,
Copied contents to your clipboard!